Learning with COVID-19 : what about anticoagulation?
Infection caused by SARS-CoV-2 (COVID-19) is associated with an increased risk of thromboembolic disease. So-me authors recommend anticoagulation at therapeutic doses for, at least, the most severely ill patients; this practice is not free of risks, which is why only thromboembolic prophylaxis is recommended by other consensuses. In the case of previously anticoagulated patients, changing the oral anticoagulant for a low molecular weight heparin (LMWH) is generally recommended. We present the cases of two patients admitted due to COVID-19, without serious clinical data, in whom anticoagulation (acenocoumarol and rivaroxaban, respectively) was replaced by LMWH at therapeutic doses, both presenting abdominal bleeding. This type of bleeding is an infrequent complication in anticoagulated patients, but the concurrence of two cases in a short period of time in the context of the COVID-19 pandemic leads us to consider that there is not yet any clear evidence on therapeutic anticoagulation in SARS-CoV-2 infection.
| Errataetall: |
CommentIn: An Sist Sanit Navar. 2021 Apr 28;44(1):127-128. - PMID 33853211 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Anales del sistema sanitario de Navarra - 43(2020), 2 vom: 31. Aug., Seite 251-254 |
| Sprache: |
Spanisch |
|---|
| Beteiligte Personen: |
Álvarez-Rodríguez, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9NDF7JZ4M3 |
|---|
| Anmerkungen: |
Date Completed 05.10.2020 Date Revised 07.05.2021 published: Electronic CommentIn: An Sist Sanit Navar. 2021 Apr 28;44(1):127-128. - PMID 33853211 Citation Status MEDLINE |
|---|
| doi: |
10.23938/ASSN.0884 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314383263 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314383263 | ||
| 003 | DE-627 | ||
| 005 | 20231225152617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.23938/ASSN.0884 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314383263 | ||
| 035 | |a (NLM)32865189 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Álvarez-Rodríguez, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Learning with COVID-19 |b what about anticoagulation? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2020 | ||
| 500 | |a Date Revised 07.05.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: An Sist Sanit Navar. 2021 Apr 28;44(1):127-128. - PMID 33853211 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Infection caused by SARS-CoV-2 (COVID-19) is associated with an increased risk of thromboembolic disease. So-me authors recommend anticoagulation at therapeutic doses for, at least, the most severely ill patients; this practice is not free of risks, which is why only thromboembolic prophylaxis is recommended by other consensuses. In the case of previously anticoagulated patients, changing the oral anticoagulant for a low molecular weight heparin (LMWH) is generally recommended. We present the cases of two patients admitted due to COVID-19, without serious clinical data, in whom anticoagulation (acenocoumarol and rivaroxaban, respectively) was replaced by LMWH at therapeutic doses, both presenting abdominal bleeding. This type of bleeding is an infrequent complication in anticoagulated patients, but the concurrence of two cases in a short period of time in the context of the COVID-19 pandemic leads us to consider that there is not yet any clear evidence on therapeutic anticoagulation in SARS-CoV-2 infection | ||
| 650 | 4 | |a Case Reports | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 650 | 7 | |a Acenocoumarol |2 NLM | |
| 650 | 7 | |a I6WP63U32H |2 NLM | |
| 700 | 1 | |a González González, R |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Gárate, R |e verfasserin |4 aut | |
| 700 | 1 | |a López-Riquelme, P |e verfasserin |4 aut | |
| 700 | 1 | |a González Martil, I |e verfasserin |4 aut | |
| 700 | 1 | |a Abad Cuñado, V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anales del sistema sanitario de Navarra |d 1997 |g 43(2020), 2 vom: 31. Aug., Seite 251-254 |w (DE-627)NLM09649705X |x 2340-3527 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2020 |g number:2 |g day:31 |g month:08 |g pages:251-254 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23938/ASSN.0884 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2020 |e 2 |b 31 |c 08 |h 251-254 | ||